Placebo to match
Sponsors
Olatec Therapeutics LLC, Eli Lilly & Co., AstraZeneca
Conditions
Atherosclerosis Cardiovascular DiseaseCOPDChronic Kidney DiseaseChronic Obstructive Pulmonary Disease (COPD)Diabetes, Type IIEndocrinologyHealthyHealthy Subjects
Phase 1
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683
CompletedNCT01419600
Start: 2011-10-31End: 2012-05-31Updated: 2012-07-03
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594
CompletedNCT01636024
Start: 2012-09-30End: 2013-06-30Updated: 2013-06-20
A First Time in Man Study to Asses the Safety and Tolerability of AZD7624 in Healthy Subjects
CompletedNCT01754844
Start: 2013-01-31End: 2013-08-31Updated: 2015-04-02
To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD Patients
CompletedNCT01817855
Start: 2013-09-30End: 2014-10-31Updated: 2016-03-30
A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males
TerminatedNCT02072993
Start: 2014-03-31End: 2014-07-31Updated: 2014-07-29
Phase 2
A Multi-Center Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects with an Acute Gout Flare
RecruitingCTIS2024-518844-20-00
Start: 2023-10-03Target: 98Updated: 2025-12-16
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Active, not recruitingNCT06851858
Start: 2025-03-12End: 2026-05-27Updated: 2026-03-03